文献速递艾滋病与性传播感染

换用整合酶抑制剂后体重增加的风险因素

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本研究基于AIDS临床试验组A5001和A5322队列,纳入1997-2017年随访期间换用整合酶链转移抑制剂(INSTI)方案的HIV感染者,采用分段线性混合效应模型分析换药前后体重和腰围变化。在病毒载量抑制的691人中,女性、黑人和≥60岁者在换药后2年体重增加更明显;调整模型中女性换药时白人/黑人种族、年龄≥60岁和BMI≥30与更大体重增加相关,男性中年龄≥60岁是最强风险因素。结论认为换用INSTI后年体重增加加快,尤其女性、黑人和≥60岁人群,腰围同步增加提示脂肪量增加。

要点

  • 换用INSTI后年体重增加加快,女性、黑人和≥60岁者更明显。
  • 女性换药时BMI≥30、白人/黑人种族和年龄≥60岁与更大增重相关。
  • 男性中年龄≥60岁是换药后体重增加的最强风险因素。

核心结论

  • 换用INSTI后年体重增加加快,尤其女性、黑人和≥60岁人群,腰围同步增加提示脂肪量增加。

研究设计与样本

  • 基于AIDS临床试验组A5001和A5322队列,纳入1997-2017年随访期间换用INSTI方案的972人,其中病毒载量抑制者691人。
  • 采用分段线性混合效应模型分析换药前后体重和腰围变化,调整年龄、性别、种族/民族、基线BMI、CD4+ T细胞计数、吸烟、糖尿病和随访时间。

主要发现

  • 换药者中81%为男性,50%为非白人,换药时中位年龄50岁、CD4+ T细胞计数512 cells/μL、BMI 26.4 kg/m2。
  • 在病毒载量抑制的691人中,女性、黑人和≥60岁者换药后2年体重增加大于换药前。
  • 调整模型中,女性换药时白人/黑人种族、年龄≥60岁和BMI≥30 kg/m2与更大体重增加相关;男性中年龄≥60岁是最强风险因素。
  • 腰围变化趋势与体重相似。

临床怎么用

  • 对换用INSTI的HIV感染者,尤其女性、黑人和≥60岁者,应关注体重和腰围变化。
  • 女性换药时BMI≥30 kg/m2者增重风险更高,需加强体重管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain. Whether similar gains are seen after switch to INSTIs among virologically suppressed persons is less clear. We assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322). METHODS: Participants who were in follow-up from 1997-2017 and switched to INSTI-based antiretroviral regimens were included. Piecewise linear mixed-effects models adjusting for age, sex, race/ethnicity, baseline BMI, nadir and current CD4+ T-cell count, smoking, diabetes and follow-up time with suppressed HIV-1 RNA examined weight and waist circumference change before and after first switch to INSTIs. Linear spline models with a single knot at time of switch accounted for nonlinear trends. RESULTS: The 972 participants who switched to INSTIs were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512 cells/μL, and BMI 26.4 kg/m2. Restricting to persons with suppressed HIV-1 RNA at switch (n = 691), women, blacks, and persons ≥60 years experienced greater weight gain in the 2 years after versus before switch. In adjusted models, white or black race, age ≥60, and BMI ≥30 kg/m2 at switch were associated with greater weight gain following switch among women; age ≥60 was the greatest risk factor among men. Trends for waist circumference were similar. CONCLUSIONS: Yearly weight gain increased following switch to INSTIs, particularly for women, blacks, and persons aged ≥60. Concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lake JE, Wu K, Bares SH, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2020. PMID: 32099991. doi:10.1093/cid/ciaa177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。